Concepedia

Stanislav Lechpammer

SL

Statistics

Publications

11

Citations

438

H-Index

10

Active since

1997

Affiliations

Harvard University(Current)

Astellas Pharma (United States)

Pfizer (United States)

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Stanislav Lechpammer is an author at Harvard University specializing in oncology, chemotherapy, and life sciences.

Publications per year

1997–2021

11

Publications

11

Hypoxia Inhibition of Adipocytogenesis in Human Bone Marrow Stromal Cells Requires Transforming Growth Factor-β/Smad3 Signaling

Shuanhu Zhou, Stanislav Lechpammer, Joel S. Greenberger et al. · Journal of Biological Chemistry · 2005 · 95 citations · Full text

, , +17

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang et al. · Prostate Cancer and Prostatic Diseases · 2021 · 60 citations · Full text

, , +17

Double-stranded RNA-dependent Protein Kinase (pkr) Is Essential for Thermotolerance, Accumulation of HSP70, and Stabilization of ARE-containing HSP70 mRNA during Stress

Meijuan Zhao, Dan Tang, Stanislav Lechpammer et al. · Journal of Biological Chemistry · 2002 · 53 citations · Full text

, , +17

Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy

Mirna Lechpammer, Josip Lukač, Stanislav Lechpammer et al. · International Journal of Colorectal Disease · 2004 · 51 citations

, , +14

The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies

Ze’ev Gechtman, Adina Belleli, Stanislav Lechpammer et al. · Biochemical Journal · 1997 · 44 citations · Full text

, , +17

1–5 of 11